
The Danish diagnostics company Medical Prognosis Institute (MPI) has presented promising results for a new type of biomarker test, able to predict the efficacy of the chemotherapy epirubicin, one the of most used drugs in breast cancer treatment.
CEO Peter Buhl Jensen has high expectations for the test which is to be used with a new alternative edition of the chemotherapy drug.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app